StreetInsider.com News Articles

BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism

Mon, 13 Jul 2026 08:00:00 -0400

Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained as optional future indications

Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today announced the prioritization of its lead clinical-stage asset, BETR-001, to pursue migraine and other primary headache disorders as its lead indications. The strategic focus concentrates BETR-001's development on one of the largest, most disabling and most underserved areas of neurology, and does so through a serotonin-receptor mechanism of action that is already clinically validated

BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism

Mon, 13 Jul 2026 08:00:00 -0400

BetterLife Pharma adds legal veteran to board, reports warrant proceeds

Thu, 09 Jul 2026 08:02:08 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has appointed John W. LaRocca to its board of directors and audit committee, the Vancouver-based biotechnology company announced.

LaRocca brings roughly 30 years of biopharmaceutical industry experience, having served as chief legal officer, corporate secretary, and founding chief compliance officer at four NYSE- and Nasdaq-listed companies. His prior roles include corporate secretary positions at Y-mAbs Therapeutics, Aerie Pharmaceuticals, and Eagle Pharmaceuticals.

On the transactional side, LaRocca served as principal legal officer on the $930 million sale of Aerie Pharmaceuticals to Alcon Laboratories and the $412 million sale of Y-mAbs Therapeutics to SERB Pharmaceuticals.

BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee

Thu, 09 Jul 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of John W. LaRocca, Esq. to its Board of Directors. Mr. LaRocca will also serve as a member of the Company's Audit Committee.

Mr. LaRocca is a three-decade biopharmaceutical industry executive with extensive public company seasoning across the full life-sciences lifecycle, spanning generics, branded specialty pharma, commercial biotech, and pre-commercial pipeline assets. He has served as Chief Legal Officer, Corporate Secretary,

BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee

Thu, 09 Jul 2026 08:00:00 -0400

BetterLife Pharma hires Nucro-Technics for final BETR-001 toxicology study

Mon, 06 Jul 2026 08:02:13 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has engaged Nucro-Technics Inc. to conduct the final IND-enabling GLP toxicology study for BETR-001, its non-hallucinogenic LSD derivative in preclinical development, according to a press release.

The company projects filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in the first quarter of 2027, which would allow the drug candidate to advance to Phase 1 clinical trials.

BETR-001, chemically known as 2-bromo-lysergic acid diethylamide (2-Br-LSD), is being developed initially for migraine and cluster headache. The compound acts as an agonist of the 5-HT1B, 5-HT1D, 5-HT1F, and 5-HT2A receptors.

"We

BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1

Mon, 06 Jul 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program.

BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is a potent neuroplastogen and an agonist of the 5-HT1B, 5-HT1D, and 5-HT1F receptors, which are clinically validated targets of migraine therapies, as well as the 5-HT2A receptors. BETR-001 is being developed initially for migraine and cluster headache, two disabling

BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1

Mon, 06 Jul 2026 08:00:00 -0400

Form 6-K BetterLife Pharma Inc. For: Apr 30

Fri, 26 Jun 2026 15:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26698090.html

Form 6-K BetterLife Pharma Inc. For: Apr 30

Fri, 26 Jun 2026 15:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26698090.html

Form 6-K BetterLife Pharma Inc. For: Apr 30

Fri, 26 Jun 2026 15:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26698090.html

Form 6-K BetterLife Pharma Inc. For: Jun 25

Thu, 25 Jun 2026 14:26:00 -0400

si-local-file:///var/storage/secattach/20260625/26691485.html

Form 6-K BetterLife Pharma Inc. For: Jun 25

Thu, 25 Jun 2026 14:26:00 -0400

si-local-file:///var/storage/secattach/20260625/26691485.html

Form 6-K BetterLife Pharma Inc. For: Jun 25

Thu, 25 Jun 2026 14:26:00 -0400

si-local-file:///var/storage/secattach/20260625/26691485.html

BetterLife Pharma hires Syner-G for GMP manufacturing of BETR-001

Thu, 25 Jun 2026 08:02:26 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has entered into an agreement with Syner-G BioPharma Group to oversee good manufacturing practice (GMP) production of its lead drug candidate, BETR-001, as part of the company's planned investigational new drug (IND) application and Phase 1 clinical program, according to a press release.

BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), described by the company as a non-hallucinogenic derivative of LSD. The compound targets neuroreceptors associated with migraines, cluster headaches, depression, and anxiety. BetterLife states BETR-001 is completing final IND-enabling studies, with an IND filing and Phase 1 trial start projected for the first

BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1

Thu, 25 Jun 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Syner-G BioPharma Group ("Syner-G") to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program.

BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is active against neuroreceptors involved in migraines and cluster headaches, as well as neuroreceptors involved in psychiatric disorders such as depression and anxiety. While it is a potent neuroplastogen and an agonist of the 5-HT2A, 5-HT1B, 5-HT1D, and 5-HT1F receptors, BETR-001 is designed to

BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1

Thu, 25 Jun 2026 08:00:00 -0400

BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing

Mon, 22 Jun 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD $2,000,000 convertible debenture financing ("Debenture" or "Financing"). The Debenture will fund the remaining IND-enabling work on the Company's lead candidate, BETR-001, as BetterLife sharpens its focus on neurological pain indications, with an initial emphasis on cluster headache and migraine.

The Financing is the first capital deployed since the Company appointed Doug Drysdale as Executive Chairman and Director on May 13, 2026. Mr. Drysdale, formerly CEO of Cybin Inc., led that company from molecule inception to Phase

BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing

Mon, 22 Jun 2026 08:00:00 -0400

Form 20-F BetterLife Pharma Inc. For: Jan 31

Mon, 01 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260601/26584076.html

Form 20-F BetterLife Pharma Inc. For: Jan 31

Mon, 01 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260601/26584076.html

Form 20-F BetterLife Pharma Inc. For: Jan 31

Mon, 01 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260601/26584076.html

BetterLife Pharma names Doug Drysdale as Executive Chairman

Wed, 13 May 2026 08:05:45 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) announced the appointment of Doug Drysdale as Executive Chairman and Director. Drysdale previously served as CEO of Cybin Inc. (NYSE: CYBN) and has been working as a corporate advisor for BetterLife.

During his tenure at Cybin, Drysdale led the company from molecule inception to Phase 3 trials over three years. The company granted Drysdale stock options to purchase 3,500,000 common shares at an exercise price of $0.065, with monthly vesting over 24 months and a 10-year term.

"We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored

BetterLife Pharma names Doug Drysdale as Executive Chairman

Wed, 13 May 2026 08:05:45 -0400

"We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director.

At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews.

"We are delighted